Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

23.88
+0.49502.12%
Volume:641.77K
Turnover:15.33M
Market Cap:2.99B
PE:110.83
High:24.18
Open:23.63
Low:23.59
Close:23.38
52wk High:31.77
52wk Low:16.57
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.58
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:13.54
PE(LYR):-188.20

Loading ...

Arcutis EVP, Chief Legal Officer Masaru Matsuda Sells 9,989 Shares for $249,861

Reuters
·
Yesterday

S&P 500 to Add Bloom Energy, Illumina and Everpure in September Rebalance

Tiger Newspress
·
Sep 05

Arcutis Biotherapeutics Grants 57,000 RSUs to 11 New Hires Under Inducement Plan

Reuters
·
Sep 05

Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
Sep 05

Arcutis Director Terrie Curran Disposes of Common Shares Worth $279,129.66

Reuters
·
Aug 29

Is Arcutis Biotherapeutics (ARQT) Stock Too Rich To Stay Reasonable?

Simply Wall St.
·
Aug 27

Insider Move at Arcutis Biotherapeutics Sends Strong Signal to Investors

TIPRANKS
·
Aug 25

Arcutis Biotherapeutics Director Terrie Curran Disposes of 1,072 Common Shares Worth $27,927.31

Reuters
·
Aug 25

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

Top Arcutis Executive Makes Notable Move With Latest Stock Sale

TIPRANKS
·
Aug 22

Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis

TIPRANKS
·
Aug 22

Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis

MT Newswires Live
·
Aug 21

Arcutis Canada: Przoryve Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
Aug 21

Arcutis Biotherapeutics Director Howard G. Welgus Sells 4,730 Common Shares for $123,835.71

Reuters
·
Aug 20

Arcutis EVP, Chief Medical Officer Patrick Burnett Disposes of USD 392,075.19 in Common Shares

Reuters
·
Aug 14

Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study

TIPRANKS
·
Aug 14

Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum

TIPRANKS
·
Aug 12

Arcutis Biotherapeutics Rilis Transkrip Paparan Kinerja Kuartal II 2026

Reuters
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
Aug 11

Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance

Simply Wall St.
·
Aug 10